Sagimet reports 52-week Phase 3 OLE results for denifanstat in acne

Sagimet Biosciences announced 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate-to-severe acne vulgaris. Denifanstat showed progressive and sustained improvements across all efficacy endpoints, including 57% IGA success, 72% reduction in total lesions and 77% reduction in inflammatory lesions, and was generally well tolerated with no adverse event-related permanent discontinuations.

Detected & updated continuously · Source: Nebula